Alkem Labs Share: Revenue Badhi **10.7%**, Ab MedTech Mein Bhi Entry! Kya Yeh Game Changer Hai?

OTHER
Whalesbook Logo
AuthorIshaan Verma|Published at:
Alkem Labs Share: Revenue Badhi **10.7%**, Ab MedTech Mein Bhi Entry! Kya Yeh Game Changer Hai?
Overview

Alkem Labs ke investors ke liye Q3 result aa gaya hai! Company ka revenue **10.7%** badh kar **₹3,736.8 Crore** ho gaya hai. Profit bhi **1.6%** badha hai, haan, thoda exceptional item ka effect tha. Par sabse bada dhamaka toh ye hai ki Alkem ab MedTech mein bhi enter kar raha hai, Swiss firm Occlutech mein **55%** stake khareed liya hai!

Chalo, numbers ko thoda aur detail mein dekhte hain. Is quarter mein Alkem Labs ka revenue 10.7% badha, jo ki ₹3,736.8 Crore hai. International sales ne toh kamaal kar diya, 26.6% jump dikhaya! Domestic sales 5.5% badhi. Profit 1.6% grow hokar ₹636 Crore tak pahuncha. Ye profit growth thodi slow isliye lagi kyunki ek exceptional item tha, ₹52.8 Crore ka, jo labour codes se related tha.

Ab baat karte hain sabse bade dhamake ki - MedTech mein entry! Alkem ne Swiss company Occlutech mein 55% stake khareeda hai, jiske liye around ₹1,074 Crore kharch kiye hain. Yeh company heart ke minimally invasive devices banati hai. Europe mein ye dusre number par hai aur duniya mein teesre number par. Indian MedTech market future mein bahut bada hone wala hai, $50 billion tak pahunch sakta hai 2030 tak. Occlutech already profitable hai aur iska gross margin 73% hai. Management ko umeed hai ki ye company 3-5 saal mein ₹1,000 Crore ka revenue de sakti hai. US mein inka PFO product June 2027 tak aa sakta hai.

Company ka EBITDA bhi 9% badh kar ₹828 Crore raha, aur margin 22.2% tha. R&D par 3.7% kharch kiya. Domestic business mein bhi growth target achha hai.

Par bhai, ek tension wali baat bhi hai. Amgen ne Alkem par litigation daal di hai unke Denosumab biosimilar ke liye. Is wajah se US mein is product ka launch 2026 ke baad delay ho sakta hai. Yeh ek important growth driver tha, toh iska impact dekhna padega.

Agar competitors ki baat karein, toh Sun Pharma aur Dr. Reddy's jaise players bhi acha perform kar rahe hain. Lekin Alkem ka MedTech mein yeh strategical move usko future mein kaafi strong bana sakta hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.